A.P.E.X. Events: John Carreyrou, A Silicon Valley Secret

Published: February 26, 2019 | Read Time: 2 minutes

poster invitation to APEX event speaker John CarreyrouA.P.E.X. Events – 91ɬÂþ’s Premier Event Series – presents the two-time Pulitzer Prize-winning author and Eccles Visiting Scholar, John Carreyrou! A career full of investigative journalism has given him a repository of secrets within various industries. His A.P.E.X. Event, Bad Blood will shed light on “Secrets and Lies in a Silicon Valley Startup.” You are invited to Carreyrou’s event on Tuesday, March 5, at 11:30 AM, in the Great Hall on 91ɬÂþ’s campus. His book, Bad Blood will be available for purchase and signing.

Mr. Carreyrou is visiting 91ɬÂþ with the generous support of The George S. and Dolores Dore Eccles Foundation Visiting Scholar Program, which provides a way for the University to invite nationally recognized scholars to campus. The program also creates an opportunity for students and faculty to network with scholars and builds lifelong working relationships.

Visit the 91ɬÂþ A.P.E.X. Event Series website for more information on this event.

John Carreyrou is a two-time Pulitzer Prize-winning investigative reporter at the Wall Street Journal. For his extensive coverage of Theranos (a Silicon Valley startup), Carreyrou was awarded the George Polk Award for Financial Reporting, the Gerald Loeb Award for Distinguished Business and Financial Journalism in the category of beat reporting, and the Barlett & Steele Silver Award for Investigative Business Journalism. His book, Bad Blood was named the Financial Times & McKinsey Business Book of the Year. Carreyrou lives in Brooklyn, New York, with his wife and three children.

“In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup “unicorn” promised to revolutionize the medical industry with a machine that would make blood testing significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes’s worth at an estimated $4.7 billion. There was just one problem: The technology didn’t work. A riveting story of the biggest corporate fraud since Enron, a tale of ambition and hubris set amid the bold promises of Silicon Valley.” (Penguin Random House)

"This is an event that I am so very excited for! What an incredible opportunity it is for us to have Mr. Carreyrou at 91ɬÂþ to talk about a scandal that has been so widely publicized. This is definitely one to be sure to see!” (Lynn Vartan, Director of A.P.E.X. Events)


Tags: APEX

Contact Information:

435-586-5400
Contact the Office of Marketing Communication

This article was published more than 3 years ago and might contain outdated information or broken links. As a result, its accuracy cannot be guaranteed.